LGLei Gao

Lei Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lei Gao has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Huan Liu

    Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine in Tongji University

    2 shared publications
  • Jialin Meng

    Department of Urology the First Affiliated Hospital of Anhui Medical University Hefei China

    2 shared publications
  • Jie Li

    Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine in Tongji University, Shanghai, China

    2 shared publications
  • Shenglin Gao

    Department of Urology, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

    2 shared publications
  • Yunfei Xu

    Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China

    2 shared publications
  • Anning Zhao

    Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 05000, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes

    by Huan Liu, Lei Gao, Tiancheng Xie, Jie Li, Ting-Shuai Zhai, Yunfei Xu

    Ferroptosis, an iron-dependent form of selective cell death, is involved in the development of many cancers. However, ferroptosis related genes (FRGs) in prostate cancer (PCa) are not been well studied. In this study, we collected the mRNA expression profiles and clinical information of PCa patients from TCGA and MSKCC databases. The univariate, LASSO, and multivariate Cox regression analyses were performed to construct a prognostic signature. Seven FRGs, AKR1C3, ALOXE3, ATP5MC3, CARS1, MT1G, PTGS2, and TFRC, were included to establish a risk model, which was validated in the MSKCC dataset. The results showed that the high-risk group was apparently correlated with copy number alteration load, tumor burden mutation, immune cell infiltration, mRNAsi, immunotherapy, and bicalutamide response. Moreover, we found that TFRC overexpression induced the proliferation and invasion of PCa cell lines in vitro. These results demonstrate that this risk model can accurately predict prognosis, suggesting that FRGs are promising prognostic biomarkers and potential drug targets in PCa patients.


  • Open Access

    Identification and validation of a ferroptosis-related genes based prognostic signature for prostate cancer

    by Huan Liu, Lei Gao, Jie Li, Tingshuai Zhai, Tiancheng Xie, Yunfei Xu

    Ferroptosis, an iron-dependent form of selective cell death, involves in the development of many cancers. However, systematic analysis of ferroptosis related genes (FRGs) in prostate cancer (PCa) remains to be clarified. In our research, we collected the mRNA expression profiles and clinical information of PCa patients from TCGA and MSKCC databases. The univariate, LASSO and multivariate Cox regression method were performed to construct prognostic signature in TCGA cohort. Seven FRGs, AKR1C3, ALOXE3, ATP5MC3, CARS1, MT1G, PTGS2, TFRC, were included to establish the risk model, which was validated in MSKCC dataset. Subsequently, we found that high risk group was strongly correlated with copy number alteration load, tumor burden mutation, immune cell infiltration, mRNAsi, immuetherapy and bicalutamide response. Finally, it was identified that overexpression of TFRC could induce proliferation and invasion in PCa cell lines in vitro. These results demonstrated that this risk model based on recurrence free survival (RFS) could accurately predict prognosis in PCa patients, suggesting that FRGs are promising prognostic biomarkers and drug target genes for PCa patients.


  • Open Access

    Integrative Analysis the characterization of peroxiredoxins in pan-cancer

    by Lei Gao, Jialin Meng, Chuang Yue, Xingyu Wu, Quanxin Su, Hao Wu, Ze Zhang, Qinzhou Yu, Shenglin Gao, Song Fan, et al.

    Peroxiredoxins (PRDXs) are antioxidant enzymes protein family members that involves the process of several biological functions, such as differentiation, cell growth. Considerable evidence demonstrates that PRDXs play critical roles in the occurrence and development of carcinomas. However, a systematic analysis of PRDXs in cancers is deficiency. Therefore, we perform a comprehensive analysis of PRDXs in 33 cancer types including mRNA expression profiles, genetic alterations, methylation, prognostic values, potential biological pathways and target drugs. Moreover, we validated that PRDX6 could regulate cancer cell proliferation via JAK2-STAT3 pathway and involve into the process of cell cycle in bladder cancer.

  • Open Access

    Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer

    by Lei Gao, Jialin Meng, Yong Zhang, Junfei Gu, Zhenwei Han, Shenglin Gao, Xiaolu Wang

    The dysregulation of RNA binding proteins (RBPs) play critical roles in the progression of several cancers. However, the overall functions of RBPs in prostate cancer (PCa) remain poorly understood. Therefore, we first identified 144 differentially expressed RBPs in tumors compared to normal tissues based on the TCGA dataset. Next, six RBP genes (MSI1, MBNL2, LENG9, REXO2, RNASE1, PABPC1L) were screened out as prognosis hub genes by univariate, LASSO and multivariate Cox regression and used to establish the prognostic signature. Further analysis indicated that high risk group was significantly associated with poor RFS, which was validated in the MSKCC cohort. Besides, patients in high risk group was closely associated with dysregulation of DNA damage repair pathway, copy number alteration, tumor burden mutation and low-respond to cisplatin (P < 0.001), bicalutamide (P < 0.001). Finally, three drugs (ribavirin, carmustine, carbenoxolone) were predicted using Connectivity Map. In summary, we identified a six-RBP gene signature and three candidate drugs against PCa, which may promote the individualized treatment and further improve the life quality of PCa patients.

  • Open Access

    Upregulation of lncRNA AGAP2‑AS1 is an independent predictor of poor survival in patients with clear cell renal carcinoma

    by Lei Gao, Anning Zhao, Xiaolu Wang

    Long non-coding RNA (lncRNA) AGAP2‑AS1 has been reported to be a potential biomarker for a variety of cancer types, while its function in clear cell renal carcinoma (ccRCC) has not yet been fully determined. The current study aimed to determine the value of lncRNA AGAP2‑AS1 in ccRCC based on The Cancer Genome Atlas (TCGA) database. The association between AGAP2‑AS1 expression and associated clinical characters were analyzed using the Wilcoxon signed‑rank test and logistic regression. The diagnostic value of AGAP2‑AS1 expression in ccRCC tissue was assessed using receiver operating characteristic (ROC) curve analysis. Clinicopathological characteristics associated with overall survival in patients with TCGA were analyzed using Cox regression and the Kaplan‑Meier method. Gene set enrichment analysis (GSEA) was also performed to assess the biological function of AGAP2‑AS1. The results demonstrated that increased expression of AGAP2‑AS1 in ccRCC was significantly associated with male, T3/T4, lymph node metastasis, distant metastasis and high tumor stage (III/IV; all, P<0.05). The area under the ROC curve (normal vs. all tumors) was revealed to be 0.891. Kaplan‑Meier survival analysis indicated that ccRCC with high lncRNA AGAP2‑AS1 exhibited a worse prognosis compared with low AGAP2‑AS1 (P<0.001). The univariate analysis revealed that high expression of AGAP2‑AS1 was significantly associated with poor overall survival [hazard ratio (HR). 1.85; 95% confidence interval (CI), 1.48‑2.33; P<0.001). Multivariate analysis revealed that AGAP2‑AS1 remained independently associated with overall survival, with a HR of 1.57 (CI, 1.21‑2.03; P<0.01). GSEA outcome demonstrated that stromal stimulation, angiogenesis, epithelial to mesenchymal transition, basal cell carcinoma, ECM receptor interaction and the Notch signaling pathway were differentially enriched in the AGAP2‑AS1 high expression phenotype. Therefore, the high expression of AGAP2‑AS1 may be an independent predictor of poor survival in patients with ccRCC.


  • Long non-coding RNA GAS5 regulates human B lymphocytic leukaemia tumourigenesis and metastasis by sponging miR-222

    by Zhenhai Jing, Lei Gao, Hongzhou Wang, Jing Chen, Ben Nie, Qing Hong

    Accumulating evidence has shown that lncRNA GAS5 is a novel tumour-promoting RNA that contributes to tumour progression by sponging miRNAs. However, the detailed role of lncRNA GAS5 in B lymphocytic leukaemia is still unclear. A qRT-PCR assay was use